Study of BL-B01D1 + TKI with or without pembrolizumab for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or metastatic kidney cancer that has been confirmed by a biopsy or other tissue test.
- You are able to provide a tumor tissue sample taken within the last 3 years.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You have not had certain treatments recently, including chemotherapy, targeted therapy, or immunotherapy, within a specific time before starting the study.
- You must not have had a previous cancer drug called a camptothecin derivative as part of an antibody-drug conjugate (ADC).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a first-line precision treatment for clear cell kidney cancer that has spread or cannot be removed. It aims to match the treatment to your cancer's protein profile to improve outcomes.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.